Shiwen Peng1, Marietta Tan2, Yen-Der Li1, Max A Cheng1, Emily Farmer1, Louise Ferrall1, Stephanie Gaillard3,4, Richard B S Roden1,3, Chien-Fu Hung1,3,4, T-C Wu5,6,7,8,9. 1. Department of Pathology, The Johns Hopkins University, Baltimore, MD, USA. 2. Department of Otolaryngology, The Johns Hopkins University, Baltimore, MD, USA. 3. Oncology, The Johns Hopkins University, Baltimore, MD, USA. 4. Obstetrics and Gynecology, The Johns Hopkins University, Baltimore, MD, USA. 5. Department of Pathology, The Johns Hopkins University, Baltimore, MD, USA. wutc@jhmi.edu. 6. Oncology, The Johns Hopkins University, Baltimore, MD, USA. wutc@jhmi.edu. 7. Obstetrics and Gynecology, The Johns Hopkins University, Baltimore, MD, USA. wutc@jhmi.edu. 8. Molecular Microbiology and Immunology, The Johns Hopkins University, Baltimore, MD, USA. wutc@jhmi.edu. 9. Johns Hopkins School of Medicine, 1550 Orleans St, CRB II - Room 309, Baltimore, MD, 21287, USA. wutc@jhmi.edu.
Abstract
INTRODUCTION: The human papillomavirus (HPV) encoded oncoproteins E6 and E7 are constitutively expressed in HPV-associated cancers, making them logical therapeutic targets. Intramuscular immunization of patients with HPV16 L2E7E6 fusion protein vaccine (TA-CIN) is well tolerated and induces HPV-specific cellular immune responses. Efficacy of PD-1 immune checkpoint blockade correlates with the level of tumor-infiltrating CD8 + T cells, yet most patients lack significant tumor infiltration of immune cells making immune checkpoint blockade suboptimal. We hypothesized that intratumoral vaccination with TA-CIN could increase the number of tumor-infiltrating CD8 + T cells, synergize with PD-1 blockade and result in better control of tumors compared with either PD-1 blockade or vaccination alone. METHODS: We examined the immunogenicity and antitumor effects of intratumoral vaccination with TA-CIN alone or in combination with PD-1 blockade in the TC-1 syngeneic murine tumor model expressing HPV16 E6/E7. RESULTS: Intratumoral vaccination with TA-CIN induced stronger antigen-specific CD8 + T cell responses and antitumor effects. Intratumoral TA-CIN vaccination generated a systemic immune response that was able to control distal TC-1 tumors. Furthermore, intratumoral TA-CIN vaccination induced tumor infiltration of antigen-specific CD8 + T cells. Knockout of Batf3 abolished antigen-specific CD8 + T cell responses and antitumor effects of intratumoral TA-CIN vaccination. Finally, PD-1 blockade synergizes with intratumoral TA-CIN vaccination resulting in significantly enhanced antigen-specific CD8 + T cell responses and complete regression of tumors, whereas either alone failed to control established TC-1 tumor. CONCLUSIONS: Our results provide rationale for future clinical testing of intratumoral TA-CIN vaccination in combination with PD-1 blockade for the control of HPV16-associated tumors.
INTRODUCTION: The human papillomavirus (HPV) encoded oncoproteins E6 and E7 are constitutively expressed in HPV-associated cancers, making them logical therapeutic targets. Intramuscular immunization of patients with HPV16 L2E7E6 fusion protein vaccine (TA-CIN) is well tolerated and induces HPV-specific cellular immune responses. Efficacy of PD-1 immune checkpoint blockade correlates with the level of tumor-infiltrating CD8 + T cells, yet most patients lack significant tumor infiltration of immune cells making immune checkpoint blockade suboptimal. We hypothesized that intratumoral vaccination with TA-CIN could increase the number of tumor-infiltrating CD8 + T cells, synergize with PD-1 blockade and result in better control of tumors compared with either PD-1 blockade or vaccination alone. METHODS: We examined the immunogenicity and antitumor effects of intratumoral vaccination with TA-CIN alone or in combination with PD-1 blockade in the TC-1 syngeneic murine tumor model expressing HPV16 E6/E7. RESULTS: Intratumoral vaccination with TA-CIN induced stronger antigen-specific CD8 + T cell responses and antitumor effects. Intratumoral TA-CIN vaccination generated a systemic immune response that was able to control distal TC-1 tumors. Furthermore, intratumoral TA-CIN vaccination induced tumor infiltration of antigen-specific CD8 + T cells. Knockout of Batf3 abolished antigen-specific CD8 + T cell responses and antitumor effects of intratumoral TA-CIN vaccination. Finally, PD-1 blockade synergizes with intratumoral TA-CIN vaccination resulting in significantly enhanced antigen-specific CD8 + T cell responses and complete regression of tumors, whereas either alone failed to control established TC-1 tumor. CONCLUSIONS: Our results provide rationale for future clinical testing of intratumoral TA-CIN vaccination in combination with PD-1 blockade for the control of HPV16-associated tumors.
Entities:
Keywords:
HPV-associated cancers; Human papillomavirus; Intratumoral; PD-1; Therapeutic vaccine
Authors: J M Walboomers; M V Jacobs; M M Manos; F X Bosch; J A Kummer; K V Shah; P J Snijders; J Peto; C J Meijer; N Muñoz Journal: J Pathol Date: 1999-09 Impact factor: 7.996
Authors: S H van der Burg; K M Kwappenberg; T O'Neill; R M Brandt; C J Melief; J K Hickling; R Offringa Journal: Vaccine Date: 2001-06-14 Impact factor: 3.641
Authors: A de Jong; T O'Neill; A Y Khan; K M C Kwappenberg; S E Chisholm; N R Whittle; J A Dobson; L C Jack; J A St Clair Roberts; R Offringa; S H van der Burg; J K Hickling Journal: Vaccine Date: 2002-10-04 Impact factor: 3.641
Authors: Allan Hildesheim; Rolando Herrero; Sholom Wacholder; Ana C Rodriguez; Diane Solomon; M Concepcion Bratti; John T Schiller; Paula Gonzalez; Gary Dubin; Carolina Porras; Silvia E Jimenez; Douglas R Lowy Journal: JAMA Date: 2007-08-15 Impact factor: 56.272
Authors: Inga I Hitzeroth; Jo-Ann S Passmore; Enid Shephard; Debbie Stewart; Martin Müller; Anna-Lise Williamson; Edward P Rybicki; W Martin Kast Journal: Vaccine Date: 2009-06-24 Impact factor: 3.641